Sparrow Pharmaceuticals
PrivateLast Round
Series B
Sep 24, 2025
Est. Valuation
$139M
Total Funding Raised
$155.2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sparrow Pharmaceuticals operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in September 2025.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for disorders related to corticosteroid excess and cardiometabolic conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sparrow Pharmaceuticals Comparables
Compare Sparrow Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stero Therapeutics | 79% | |
| Corcept Therapeutics Incorporated | 72% | |
| Recordati SpA | 67% |
For institutional investors. Book with your work email.
Sparrow Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 24, 2025 | ||||
| Series A | Apr 12, 2024 | ||||
| Series A | May 18, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sparrow Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B |
| Forbion | Series B |
| U.S. Venture Partners | Series A, Series B |
| OrbiMed | Series A, Series B |
| RiverVest Venture Partners | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 56% MoM.
- Sep 24, 2025
Zach Scheiner appointed to the Board of Directors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
Sparrow Pharma appoints George Eldridge as Chief Financial Officer in Massachusetts on Sep 8th '26.
For institutional investors. Book with your work email.
Sparrow Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sparrow Pharmaceuticals's valuation, stock price, and market status.
Is Sparrow Pharmaceuticals a public or private company?
Sparrow Pharmaceuticals is a private company.
What is the current stock price of Sparrow Pharmaceuticals?
Sparrow Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Sparrow Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sparrow Pharmaceuticals worth (valuation)?
Sparrow Pharmaceuticals's valuation is estimated at $139.0M based on funding round data.
Can I buy Sparrow Pharmaceuticals stock?
Sparrow Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sparrow Pharmaceuticals's last funding round?
Sparrow Pharmaceuticals's most recent funding round was Series B on September 24, 2025.
Who are the main investors in Sparrow Pharmaceuticals?
Key investors in Sparrow Pharmaceuticals include RA Capital Management, Forbion, OrbiMed.
Will Sparrow Pharmaceuticals IPO soon?
No public IPO plans have been announced for Sparrow Pharmaceuticals.
How can I track Sparrow Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Sparrow Pharmaceuticals's shares on secondary markets.